— AstraZeneca (NYSE: AZN) reported fourth quarter 2019 earnings of $0.24 per share and core earnings of $0.89 per share.
— Revenue rose 8% to $6.66 billion vs. $6.75 billion expected. Products sales rose 8% year-over-year to $6.25 billion.
— Oncology sales advanced by 29% and respiratory sales grew by 13%. Biopharmaceuticals sales increased by 10% and new CVRM sales rose by 6% while sales in other medicines fell by 17%.
— Depending on the impact of the novel coronavirus (Covid-19) outbreak, AstraZeneca expects FY20 revenue to increase by a high single-digit to a low double-digit percentage and core EPS is expected to increase by a mid- to high-teens percentage.
— Guidance assumes an unfavourable impact from China lasting up to a few months as a result of the recent novel coronavirus (Covid-19) outbreak.
— AZN stock, which advanced 4% in the last three months, was down slightly during the before-market session.
Most Popular
Omnichannel push, margin dynamics in focus as Walmart gears up for Q3 earnings
Walmart Inc. (NYSE: WMT) entered the second half of FY26 navigating a challenging retail landscape marked by tariff-related cost pressure and cautious consumer behavior. At the same time, the company
AMAT Earnings: Applied Materials Q4 adjusted profit drops on lower revenues
Semiconductor equipment maker Applied Materials, Inc. (NASDAQ: AMAT) on Thursday reported a decrease in adjusted earnings for the fourth quarter of fiscal 2025. Adjusted earnings declined to $2.17 per share
Disney’s (DIS) streaming business continues its momentum in Q4 2025
Shares of The Walt Disney Company (NYSE: DIS) fell 9% on Thursday after the company delivered mixed results for the fourth quarter of 2025. While earnings beat expectations, revenues fell
